Djordje Atanackovic

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2017 · 277 citations · Full text

Hematological Malignancy, Plasma Cells, Bone Marrow Failure +14

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol et al. · The Lancet Haematology · 2019 · 237 citations · Full text

Hematological Malignancy, Medicine, Immunology +7

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2018 · 203 citations · Full text

Hematological Malignancy, Medicine, Hematology +10

Survey of naturally occurring CD4 ⁺ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

Sacha Gnjatic, Djordje Atanackovic, Elke Jäger et al. · Proceedings of the National Academy of Sciences · 2003 · 201 citations · Full text